Cargando…

Pan-Cancer Analysis Identifies Tumor Cell Surface Targets for CAR-T Cell Therapies and Antibody Drug Conjugates

SIMPLE SUMMARY: Identification of tumor cell surface targets is vital for chimeric antigen receptor-T cell (CAR-T) therapies and antibody drug conjugates (ADCs). This study utilized the Cancer Genome Atlas (TCGA) database to perform a series of conditional screenings of tumor-specific surface protei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xinhui, Zhou, Jian, Zhang, Weiwen, You, Wenhua, Wang, Jun, Zhou, Linlin, Liu, Lei, Chen, Wei-Wei, Li, Hanjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688665/ https://www.ncbi.nlm.nih.gov/pubmed/36428765 http://dx.doi.org/10.3390/cancers14225674

Ejemplares similares

Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancer
por: Schettini, F., et al.
Publicado: (2021)

Pan-cancer distribution of cleaved cell-surface amphiregulin, the target of the GMF-1A3 antibody drug conjugate
por: Lofgren, Kristopher A, et al.
Publicado: (2022)

Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies
por: Han, Lu, et al.
Publicado: (2021)

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
por: Berahovich, Robert, et al.
Publicado: (2018)

The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2021)

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
por: Jain, Neeraj, et al.
Publicado: (2023)

P836: ANTIBODY-DRUG CONJUGATES AS POTENTIAL CAR-T CELL SPECIFIC OFF-SWITCH IN MULTIPLE MYELOMA
por: Bielowski, Anna, et al.
Publicado: (2023)

Advances in Universal CAR-T Cell Therapy
por: Lin, Haolong, et al.
Publicado: (2021)

Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers
por: Li, Yongsheng, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma
por: Kapinos, Kandice A., et al.
Publicado: (2023)

China enters CAR-T cell therapy era
por: Cao, Xin, et al.
Publicado: (2021)

DEMONSTRATION OF SURFACE ANTIGENS AND PINOCYTOSIS IN MAMMALIAN CELLS WITH FERRITIN-ANTIBODY CONJUGATES
por: Easton, John M., et al.
Publicado: (1962)

Surface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells
por: Luks, Valerie L., et al.
Publicado: (2022)

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
por: Han, Lu, et al.
Publicado: (2020)

Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform
por: Borrok, M. Jack, et al.
Publicado: (2022)

Reduced ABO blood group antibody titers in patients after CD19 CAR-T cell therapy
por: Li, Qiang, et al.
Publicado: (2022)

Impact of the conjugation of antibodies to the surfaces of polymer nanoparticles on the immune cell targeting abilities
por: Lee, Na Kyeong, et al.
Publicado: (2021)

The aberrant expression of rhythm genes affects the genome instability and regulates the cancer immunity in pan‐cancer
por: Zhou, Jian, et al.
Publicado: (2020)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo
por: Ho, Jin-Yuan, et al.
Publicado: (2021)

A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy
por: Li, Tongjuan, et al.
Publicado: (2019)

Erratum to: CAR T Cell Therapy for Hematological Malignancies
por: Yang, Xin, et al.
Publicado: (2021)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain
por: Li, Tongjuan, et al.
Publicado: (2020)

Epithelial cell adhesion efficacy of a novel peptide identified by panning on a smooth titanium surface
por: Kihara, Hidemichi, et al.
Publicado: (2018)

A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate
por: Xiao, Dian, et al.
Publicado: (2021)

Current state of CAR-T therapy for T-cell malignancies
por: Luo, Liangkui, et al.
Publicado: (2022)

Detection of Circulating Tumor Cells in Hepatocellular Carcinoma Using Antibodies against Asialoglycoprotein Receptor, Carbamoyl Phosphate Synthetase 1 and Pan-Cytokeratin
por: Li, Jun, et al.
Publicado: (2014)

CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy
por: Shademan, Behrouz, et al.
Publicado: (2022)

CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins
por: Jost, Christian, et al.
Publicado: (2020)

Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC
por: Li, Dezhi, et al.
Publicado: (2023)

Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph(+) B cell acute lymphoblastic leukemia
por: Han, Lu, et al.
Publicado: (2022)

Pan-Cancer Transcriptomic Analysis Identifies PLK1 Crucial for the Tumorigenesis of Clear Cell Renal Cell Carcinoma
por: Qian, Yiguan, et al.
Publicado: (2022)

Computational Construction of Antibody–Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable Linker
por: Filntisi, Arianna, et al.
Publicado: (2014)

THE LOCALIZATION OF SPECTRIN ON THE INNER SURFACE OF HUMAN RED BLOOD CELL MEMBRANES BY FERRITIN-CONJUGATED ANTIBODIES
por: Nicolson, Garth L., et al.
Publicado: (1971)

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells
por: Thakur, Archana, et al.
Publicado: (2021)

Antibody–drug conjugates: Recent advances in payloads
por: Wang, Zhijia, et al.
Publicado: (2023)

Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control
por: Tang, Yubo, et al.
Publicado: (2017)

A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells
por: Tan, Xiaoding, et al.
Publicado: (2023)

Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies
por: Kang, Xiuhua, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gitsbu719q59d1jl24htsdfur7